organization · Reporting owner

Cormorant Private Healthcare Fund II, LP

Disclosed activity across 12 companies

Tapewire entity: 74740
SEC CIK: 0001747677

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Erasca, Inc.ERAS · Entity 3796	Director	June 22, 2023	June 26, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Erasca, Inc.

Report date June 22, 2023 · Filed June 26, 2023

Jointly reported with Chen Bihua, Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.66 · Expires 2033-06-21	Direct	60,000	Reported balance After 2023-06-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-06-22 · Grant · Acquired 60,000 · Balance 60,000 F4: 100% of the options to purchase shares vest on 6/22/2024, subject to the Reporting Person's continuous service to the Issuer on such vesting date. F5: Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.81 · Expires 2031-04-11	Direct	166,666	Reported balance Holding disclosure · report date 2023-06-22 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 166,666 F3: Stock option grant for 166,666 shares, 41,667 shares of which become exercisable on 3/16/2022 and 124,999 shares of which become exercisable thereafter in equal monthly installments through 3/16/2025. F5: Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2032-06-21	Direct	40,000	Reported balance Holding disclosure · report date 2023-06-22 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 40,000 F5: Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	10,813,246	Reported balance Holding disclosure · report date 2023-06-22 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 10,813,246 F1: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F2: Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.

Filing footnotes · ownership attribution and instrument terms

F1: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F2: Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.

F3: Stock option grant for 166,666 shares, 41,667 shares of which become exercisable on 3/16/2022 and 124,999 shares of which become exercisable thereafter in equal monthly installments through 3/16/2025.

F4: 100% of the options to purchase shares vest on 6/22/2024, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

F5: Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.

Past disclosures · reporting ended (11)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Akouos, Inc.

Report date June 30, 2020 · Filed July 02, 2020

Jointly reported with Cormorant Asset Management, LP, Chen Bihua, Cormorant Global Healthcare Master Fund, LP

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	499,989	Reported balance After 2020-06-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-06-30 · Conversion · Acquired 499,989 · Balance 499,989 F1: Shares of Series B Convertible Preferred Stock ("Series B Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: The Series B Preferred Stock represented, on an as-converted basis (i) 99,493 shares of Common Stock held by the Master Fund, (ii) 394,500 shares of Common Stock held by Fund II, and (iii) 5,996 shares of Common Stock held by the Account.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	789,989	Reported balance After 2020-06-30 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-06-30 · Purchase · Acquired 290,000 · Balance 789,989 F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: Shares reported herein as purchased on June 30, 2020 represent (i) 274,543 shares purchased by the Master Fund, and (ii) 15,457 shares purchased by the Account.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-06-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-06-30 · Conversion · Acquired 499,989 · Balance 0 F1: Shares of Series B Convertible Preferred Stock ("Series B Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F3: The Series B Preferred Stock represented, on an as-converted basis (i) 99,493 shares of Common Stock held by the Master Fund, (ii) 394,500 shares of Common Stock held by Fund II, and (iii) 5,996 shares of Common Stock held by the Account. F4: Shares reported herein as purchased on June 30, 2020 represent (i) 274,543 shares purchased by the Master Fund, and (ii) 15,457 shares purchased by the Account.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series B Convertible Preferred Stock ("Series B Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.

F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: The Series B Preferred Stock represented, on an as-converted basis (i) 99,493 shares of Common Stock held by the Master Fund, (ii) 394,500 shares of Common Stock held by Fund II, and (iii) 5,996 shares of Common Stock held by the Account.

F4: Shares reported herein as purchased on June 30, 2020 represent (i) 274,543 shares purchased by the Master Fund, and (ii) 15,457 shares purchased by the Account.

Atea Pharmaceuticals, Inc.

Report date November 03, 2020 · Filed November 05, 2020

Jointly reported with Cormorant Asset Management, LP, Chen Bihua, Cormorant Global Healthcare Master Fund, LP, CORMORANT PRIVATE HEALTHCARE FUND I, LP

Section 16 reporting ended · disclosed 2020-11-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	6,411,355	Reported balance After 2020-11-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-11-03 · Conversion · Acquired 6,411,355 · Balance 6,411,355 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: Represents (i) 2,043,170 shares of Common Stock held by the Master Fund, (ii) 3,106,168 shares of Common Stock held by Fund I, (iii) 912,612 shares of Common Stock held by Fund II, and (iv) 349,405 shares of Common Stock held by the Account.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-03 · Conversion · Disposed 1,000,000 · Balance 0 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 842,500 shares held by the Master Fund and (ii) 157,500 shares held by the Account.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-03 · Conversion · Disposed 1,650,165 · Balance 0 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 396,040 shares held by the Master Fund, (ii) 1,155,115 shares held by Fund I, and (iii) 99,010 shares held by the Account.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-03 · Conversion · Disposed 2,631,580 · Balance 0 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 587,632 shares held by the Master Fund, (ii) 1,951,053 shares held by Fund I, and (iii) 92,895 shares held by the Account.
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-03 · Conversion · Disposed 712,250 · Balance 0 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F7: The Series D Convertible Preferred Stock represented, on an as-converted basis, (i) 136,823 shares held by the Master Fund and (ii) 575,427 shares held by Fund II.
Series D-1 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-03 · Conversion · Disposed 417,360 · Balance 0 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F8: The Series D-1 Convertible Preferred Stock represented, on an as-converted basis, (i) 80,175 shares held by the Master Fund and (ii) 337,185 shares held by Fund II.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: Represents (i) 2,043,170 shares of Common Stock held by the Master Fund, (ii) 3,106,168 shares of Common Stock held by Fund I, (iii) 912,612 shares of Common Stock held by Fund II, and (iv) 349,405 shares of Common Stock held by the Account.

F4: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 842,500 shares held by the Master Fund and (ii) 157,500 shares held by the Account.

F5: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 396,040 shares held by the Master Fund, (ii) 1,155,115 shares held by Fund I, and (iii) 99,010 shares held by the Account.

F6: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 587,632 shares held by the Master Fund, (ii) 1,951,053 shares held by Fund I, and (iii) 92,895 shares held by the Account.

F7: The Series D Convertible Preferred Stock represented, on an as-converted basis, (i) 136,823 shares held by the Master Fund and (ii) 575,427 shares held by Fund II.

F8: The Series D-1 Convertible Preferred Stock represented, on an as-converted basis, (i) 80,175 shares held by the Master Fund and (ii) 337,185 shares held by Fund II.

Avidity Biosciences, Inc.

Report date June 16, 2020 · Filed June 18, 2020

Jointly reported with Cormorant Asset Management, LP, Chen Bihua, Cormorant Global Healthcare Master Fund, LP

Section 16 reporting ended · disclosed 2020-06-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,214,545	Reported balance After 2020-06-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-06-16 · Conversion · Acquired 2,214,545 · Balance 2,214,545 F1: Shares of Series C Convertible Preferred Stock ("Series C Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: The Series C Preferred Stock represented, on an as-converted basis (i) 419,877 shares of Common Stock held by the Master Fund, (ii) 1,762,115 shares of Common Stock held by Fund II, and (iii) 32,553 shares of Common Stock held by the Account.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,514,545	Reported balance After 2020-06-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-06-16 · Purchase · Acquired 300,000 · Balance 2,514,545 F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: Shares reported herein as purchased on June 16, 2020 represent (i) 284,010 shares purchased by the Master Fund, and (ii) 15,990 shares purchased by the Account.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-06-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-06-16 · Conversion · Acquired 2,214,545 · Balance 0 F1: Shares of Series C Convertible Preferred Stock ("Series C Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F3: The Series C Preferred Stock represented, on an as-converted basis (i) 419,877 shares of Common Stock held by the Master Fund, (ii) 1,762,115 shares of Common Stock held by Fund II, and (iii) 32,553 shares of Common Stock held by the Account. F4: Shares reported herein as purchased on June 16, 2020 represent (i) 284,010 shares purchased by the Master Fund, and (ii) 15,990 shares purchased by the Account.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series C Convertible Preferred Stock ("Series C Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.

F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: The Series C Preferred Stock represented, on an as-converted basis (i) 419,877 shares of Common Stock held by the Master Fund, (ii) 1,762,115 shares of Common Stock held by Fund II, and (iii) 32,553 shares of Common Stock held by the Account.

F4: Shares reported herein as purchased on June 16, 2020 represent (i) 284,010 shares purchased by the Master Fund, and (ii) 15,990 shares purchased by the Account.

BioAtla, Inc.

Report date December 18, 2020 · Filed December 22, 2020

Jointly reported with Cormorant Asset Management, LP, Chen Bihua, Cormorant Global Healthcare Master Fund, LP

Section 16 reporting ended · disclosed 2020-12-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	1,492,060	Reported balance After 2020-12-18 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-12-18 · Conversion · Acquired 1,492,060 · Balance 1,492,060 F1: Shares of Series D Convertible Preferred Stock ("Series D Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II") and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: The Series D Preferred Stock represented, on an as-converted basis (i) 310,945 shares of Common Stock held by the Master Fund and (ii) 1,181,115 shares of Common Stock held by Fund II.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,292,060	Reported balance After 2020-12-18 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-12-18 · Purchase · Acquired 800,000 · Balance 2,292,060 F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II") and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: Shares reported herein as purchased on December 18, 2020 represent (i) 765,120 shares purchased by the Master Fund, and (ii) 34,880 shares purchased by the Account.
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-12-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-12-18 · Conversion · Disposed 1,492,060 · Balance 0 F1: Shares of Series D Convertible Preferred Stock ("Series D Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II") and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: The Series D Preferred Stock represented, on an as-converted basis (i) 310,945 shares of Common Stock held by the Master Fund and (ii) 1,181,115 shares of Common Stock held by Fund II.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series D Convertible Preferred Stock ("Series D Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.

F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II") and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: The Series D Preferred Stock represented, on an as-converted basis (i) 310,945 shares of Common Stock held by the Master Fund and (ii) 1,181,115 shares of Common Stock held by Fund II.

F4: Shares reported herein as purchased on December 18, 2020 represent (i) 765,120 shares purchased by the Master Fund, and (ii) 34,880 shares purchased by the Account.

Design Therapeutics, Inc.

Report date March 30, 2021 · Filed April 01, 2021

Jointly reported with Cormorant Asset Management, LP, Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP

Section 16 reporting ended · disclosed 2021-04-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,364,844	Reported balance After 2021-03-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-03-30 · Conversion · Acquired 4,364,844 · Balance 4,364,844 F1: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: Represents (i) 887,540 shares of Common Stock held by the Master Fund, (ii) 2,335,405 shares held by Fund II, (iii) 1,084,906 shares of Common Stock held by Fund III, and (iv) 56,993 shares of Common Stock held by the Account.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	5,114,844	Reported balance After 2021-03-30 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-03-30 · Purchase · Acquired 750,000 · Balance 5,114,844 F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: Shares reported herein as purchased on March 30, 2021 represent (i) 713,850 shares purchased by the Master Fund, and (ii) 36,150 shares purchased by the Account.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2021-03-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-03-30 · Conversion · Disposed 2,959,891 · Balance 0 F1: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 588,988 shares held by the Master Fund, (ii) 2,335,405 shares held by Fund II, and (iii) 35,498 shares held by the Account.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2021-03-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-03-30 · Conversion · Disposed 1,404,953 · Balance 0 F1: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 298,552 shares held by the Master Fund, (ii) 1,084,906 shares held by Fund III, and (iii) 21,495 shares held by the Account.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: Represents (i) 887,540 shares of Common Stock held by the Master Fund, (ii) 2,335,405 shares held by Fund II, (iii) 1,084,906 shares of Common Stock held by Fund III, and (iv) 56,993 shares of Common Stock held by the Account.

F4: Shares reported herein as purchased on March 30, 2021 represent (i) 713,850 shares purchased by the Master Fund, and (ii) 36,150 shares purchased by the Account.

F5: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 588,988 shares held by the Master Fund, (ii) 2,335,405 shares held by Fund II, and (iii) 35,498 shares held by the Account.

F6: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 298,552 shares held by the Master Fund, (ii) 1,084,906 shares held by Fund III, and (iii) 21,495 shares held by the Account.

GreenLight Biosciences Holdings, PBC

Report date July 20, 2023 · Filed July 24, 2023

Jointly reported with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Chen Bihua

Section 16 reporting ended · disclosed 2023-07-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	0	Reported balance After 2023-07-20 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-07-20 · Sale · Disposed 9,188,659 · Balance 0 F1: Pursuant to the terms of previously disclosed Contribution and Exchange Agreements, the shares reported herein were contributed to SW ParentCo, Inc. ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.001 per share, of Parent. F2: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP II, LLC ("GP II") serve as General Partner of the Master Fund and Fund II, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP II. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: Represents (i) 4,751,020 shares of Common Stock that had been beneficially owned by the Master Fund and (ii) 4,437,639 shares of Common Stock that had been beneficially owned by Fund II.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of previously disclosed Contribution and Exchange Agreements, the shares reported herein were contributed to SW ParentCo, Inc. ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.001 per share, of Parent.

F2: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP II, LLC ("GP II") serve as General Partner of the Master Fund and Fund II, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP II. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: Represents (i) 4,751,020 shares of Common Stock that had been beneficially owned by the Master Fund and (ii) 4,437,639 shares of Common Stock that had been beneficially owned by Fund II.

Jade Biosciences, Inc.

Report date July 02, 2021 · Filed July 07, 2021

Jointly reported with Cormorant Asset Management, LP, Chen Bihua, Cormorant Global Healthcare Master Fund, LP

Section 16 reporting ended · disclosed 2021-07-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	1,530,691	Reported balance After 2021-07-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-07-02 · Conversion · Acquired 1,530,691 · Balance 1,530,691 F1: Shares of Series A Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund II. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: Represents (i) 318,995 shares of Common Stock held by the Master Fund and (ii) 1,211,696 shares of Common Stock held by Fund II.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,030,691	Reported balance After 2021-07-02 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-07-02 · Purchase · Acquired 500,000 · Balance 2,030,691 F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund II. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: Shares reported herein as purchased on July 2, 2021 represent 500,000 shares purchased by the Master Fund.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2021-07-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-07-02 · Conversion · Disposed 1,530,691 · Balance 0 F1: Shares of Series A Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund II. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 318,995 shares of Common Stock held by the Master Fund and (ii) 1,211,696 shares of Common Stock held by Fund II.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series A Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund II. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: Represents (i) 318,995 shares of Common Stock held by the Master Fund and (ii) 1,211,696 shares of Common Stock held by Fund II.

F4: Shares reported herein as purchased on July 2, 2021 represent 500,000 shares purchased by the Master Fund.

F5: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 318,995 shares of Common Stock held by the Master Fund and (ii) 1,211,696 shares of Common Stock held by Fund II.

Monte Rosa Therapeutics, Inc.

Report date June 28, 2021 · Filed June 30, 2021

Jointly reported with Cormorant Asset Management, LP, Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP

Section 16 reporting ended · disclosed 2021-06-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,602,200	Reported balance After 2021-06-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-06-28 · Conversion · Acquired 2,602,200 · Balance 2,602,200 F1: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: Represents (i) 330,892 shares of Common Stock held by the Master Fund, (ii) 843,577 shares of Common Stock held by Fund II, (iii) 1,419,249 shares of Common Stock held by Fund III, and (iv) 8,482 shares of Common Stock held by the Account.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	3,202,200	Reported balance After 2021-06-28 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-06-28 · Purchase · Acquired 600,000 · Balance 3,202,200 F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: Shares reported herein as purchased on June 28, 2021 represent 600,000 shares purchased by the Master Fund.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2021-06-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-06-28 · Conversion · Acquired 2,124,343 · Balance 0 F1: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 226,242 shares of Common Stock held by the Master Fund, (ii) 843,577 shares of Common Stock held by Fund II, and (iii) 1,054,524 shares of Common Stock held by Fund III.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2021-06-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-06-28 · Conversion · Acquired 477,857 · Balance 0 F1: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 104,650 shares of Common Stock held by the Master Fund, (ii) 364,725 shares of Common Stock held by Fund III, and (iii) 8,482 shares of Common Stock held by the Account.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F3: Represents (i) 330,892 shares of Common Stock held by the Master Fund, (ii) 843,577 shares of Common Stock held by Fund II, (iii) 1,419,249 shares of Common Stock held by Fund III, and (iv) 8,482 shares of Common Stock held by the Account.

F4: Shares reported herein as purchased on June 28, 2021 represent 600,000 shares purchased by the Master Fund.

F5: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 226,242 shares of Common Stock held by the Master Fund, (ii) 843,577 shares of Common Stock held by Fund II, and (iii) 1,054,524 shares of Common Stock held by Fund III.

F6: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 104,650 shares of Common Stock held by the Master Fund, (ii) 364,725 shares of Common Stock held by Fund III, and (iii) 8,482 shares of Common Stock held by the Account.

MoonLake Immunotherapeutics

Report date September 29, 2025 · Filed October 01, 2025

Jointly reported with Chen Bihua, Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP

Section 16 reporting ended · disclosed 2025-10-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnotes	8,423,403	Reported balance After 2025-09-29 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-09-29 · Sale · Disposed 70,748 · Balance 8,423,403 F1: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $9.25 to $9.43 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund (as defined below) , Fund II (as defined below), Fund III (as defined below), Fund IV (as defined below), and the Account (as defined below). F2: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: Represents (i) 2,690,183 Shares beneficially owned by the Master Fund, (ii) 1,787,722 Shares beneficially owned by Fund II, (iii) 2,433,441 Shares beneficially owned by Fund III, (iv) 1,487,507 Shares beneficially owned by Fund IV, and (v) 24,550 shares beneficially owned by the Account.
Class A Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnotes	8,190,943	Reported balance After 2025-09-29 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-09-29 · Sale · Disposed 232,460 · Balance 8,190,943 F5: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $8.20 to $9.02 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account. F2: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6: Represents (i) 2,615,943 Shares beneficially owned by the Master Fund, (ii) 1,738,386 Shares beneficially owned by Fund II, (iii) 2,366,285 Shares beneficially owned by Fund III, (iv) 1,446,456 Shares beneficially owned by Fund IV, and (v) 23,873 shares beneficially owned by the Account.
Class A Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnotes	4,800,000	Reported balance After 2025-09-29 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-09-29 · Sale · Disposed 3,390,943 · Balance 4,800,000 F7: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $7.30 to $8.18 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account. F2: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F8: Represents (i) 1,532,978 Shares beneficially owned by the Master Fund, (ii) 1,018,717 Shares beneficially owned by Fund II, (iii) 1,386,674 Shares beneficially owned by Fund III, (iv) 847,642 Shares beneficially owned by Fund IV, and (v) 13,989 shares beneficially owned by the Account.
Class A Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnotes	2,000,000	Reported balance After 2025-09-29 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2025-09-29 · Sale · Disposed 2,800,000 · Balance 2,000,000 F9: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $6.20 to $7.04 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account. F2: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F10: Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, (iv) 353,184 Shares beneficially owned by Fund IV, and (v) 5,827 shares beneficially owned by the Account.
Class A Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnotes	1,994,173	Reported balance After 2025-09-30 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2025-09-30 · Sale · Disposed 5,827 · Balance 1,994,173 F11: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $6.94 to $6.99 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Account. F2: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F12: Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, and (iv) 353,184 Shares beneficially owned by Fund IV.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $9.25 to $9.43 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund (as defined below) , Fund II (as defined below), Fund III (as defined below), Fund IV (as defined below), and the Account (as defined below).

F2: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV.

F3: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F4: Represents (i) 2,690,183 Shares beneficially owned by the Master Fund, (ii) 1,787,722 Shares beneficially owned by Fund II, (iii) 2,433,441 Shares beneficially owned by Fund III, (iv) 1,487,507 Shares beneficially owned by Fund IV, and (v) 24,550 shares beneficially owned by the Account.

F5: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $8.20 to $9.02 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account.

F6: Represents (i) 2,615,943 Shares beneficially owned by the Master Fund, (ii) 1,738,386 Shares beneficially owned by Fund II, (iii) 2,366,285 Shares beneficially owned by Fund III, (iv) 1,446,456 Shares beneficially owned by Fund IV, and (v) 23,873 shares beneficially owned by the Account.

F7: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $7.30 to $8.18 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account.

F8: Represents (i) 1,532,978 Shares beneficially owned by the Master Fund, (ii) 1,018,717 Shares beneficially owned by Fund II, (iii) 1,386,674 Shares beneficially owned by Fund III, (iv) 847,642 Shares beneficially owned by Fund IV, and (v) 13,989 shares beneficially owned by the Account.

F9: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $6.20 to $7.04 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account.

F10: Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, (iv) 353,184 Shares beneficially owned by Fund IV, and (v) 5,827 shares beneficially owned by the Account.

F11: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $6.94 to $6.99 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Account.

F12: Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, and (iv) 353,184 Shares beneficially owned by Fund IV.

Olema Pharmaceuticals, Inc.

Report date November 23, 2020 · Filed November 23, 2020

Jointly reported with Cormorant Asset Management, LP, Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP

Section 16 reporting ended · disclosed 2020-11-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,845,544	Reported balance After 2020-11-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-11-23 · Conversion · Acquired 2,845,544 · Balance 2,845,544 F1: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: Represents (i) 538,464 shares of Common Stock held by the Master Fund, (ii) 1,684,920 shares of Common Stock held by Fund II, (iii) 587,871 shares of Common Stock held by Fund III, and (iv) 34,289 shares of Common Stock held by the Account.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	3,270,544	Reported balance After 2020-11-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-11-23 · Purchase · Acquired 425,000 · Balance 3,270,544 F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: Shares reported herein as purchased on November 23, 2020 represent (i) 404,940 shares purchased by the Master Fund, and (ii) 20,060 shares purchased by the Account.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-23 · Conversion · Disposed 2,122,367 · Balance 0 F1: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 412,342 shares held by the Master Fund, (ii) 1,684,920 shares held by Fund II, and (iii) 25,105 shares held by the Account.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-23 · Conversion · Disposed 723,177 · Balance 0 F1: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 126,122 shares held by the Master Fund, (ii) 587,871 shares held by Fund III, and (iii) 9,184 shares held by the Account.

Filing footnotes · ownership attribution and instrument terms

F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: Represents (i) 538,464 shares of Common Stock held by the Master Fund, (ii) 1,684,920 shares of Common Stock held by Fund II, (iii) 587,871 shares of Common Stock held by Fund III, and (iv) 34,289 shares of Common Stock held by the Account.

F4: Shares reported herein as purchased on November 23, 2020 represent (i) 404,940 shares purchased by the Master Fund, and (ii) 20,060 shares purchased by the Account.

F5: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 412,342 shares held by the Master Fund, (ii) 1,684,920 shares held by Fund II, and (iii) 25,105 shares held by the Account.

F6: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 126,122 shares held by the Master Fund, (ii) 587,871 shares held by Fund III, and (iii) 9,184 shares held by the Account.

Rain Oncology Inc.

Report date April 27, 2021 · Filed April 29, 2021

Jointly reported with Cormorant Asset Management, LP, Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP

Section 16 reporting ended · disclosed 2021-04-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,326,657	Reported balance After 2021-04-27 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-04-27 · Conversion · Acquired 2,326,657 · Balance 2,326,657 F1: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: Represents (i) 133,980 shares of voting common stock and 109,620 shares of non-voting common stock held by the Master Fund, (ii) 509,177 shares of voting common stock and 416,600 shares of non-voting common stock held by Fund II, and (iii) 636,504 shares of voting common stock and 520,776 shares of non-voting common stock held by the Fund III.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,776,657	Reported balance After 2021-04-27 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-04-27 · Purchase · Acquired 450,000 · Balance 2,776,657 F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: Shares reported herein as purchased on April 27, 2021 represent (i) 439,425 shares purchased by the Master Fund, and (ii) 10,575 shares purchased by the Account.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2021-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-04-27 · Conversion · Disposed 2,512,561 · Balance 0 F1: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 133,980 shares of voting common stock and 109,620 shares of non-voting common stock held by the Master Fund, (ii) 509,177 shares of voting common stock and 416,600 shares of non-voting common stock held by Fund II, and (iii) 636,504 shares of voting common stock and 520,776 shares of non-voting common stock held by the Fund III

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: Represents (i) 133,980 shares of voting common stock and 109,620 shares of non-voting common stock held by the Master Fund, (ii) 509,177 shares of voting common stock and 416,600 shares of non-voting common stock held by Fund II, and (iii) 636,504 shares of voting common stock and 520,776 shares of non-voting common stock held by the Fund III.

F4: Shares reported herein as purchased on April 27, 2021 represent (i) 439,425 shares purchased by the Master Fund, and (ii) 10,575 shares purchased by the Account.

F5: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 133,980 shares of voting common stock and 109,620 shares of non-voting common stock held by the Master Fund, (ii) 509,177 shares of voting common stock and 416,600 shares of non-voting common stock held by Fund II, and (iii) 636,504 shares of voting common stock and 520,776 shares of non-voting common stock held by the Fund III

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 30, 2025 Filed Oct 1, 2025 21:22 UTC	MoonLake Immunotherapeutics MLTX · Entity 4785	SaleClass A Ordinary Shares	5,827	$6.96	$40,555.92	Disclosure SEC source: 0000929638-25-003712 · form4.xml · nonDerivative · entry 5 Chen Bihua · CIK 0001599214 · Former 10% Owner Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,994,173 F11 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $6.94 to $6.99 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Account. F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F12 · ownership.nature: Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, and (iv) 353,184 Shares beneficially owned by Fund IV. Read SEC document
September 29, 2025 Filed Oct 1, 2025 21:22 UTC	MoonLake Immunotherapeutics MLTX · Entity 4785	SaleClass A Ordinary Shares	2,800,000	$6.61	$18,508,000.00	Disclosure SEC source: 0000929638-25-003712 · form4.xml · nonDerivative · entry 4 Chen Bihua · CIK 0001599214 · Former 10% Owner Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,000,000 F9 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $6.20 to $7.04 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account. F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F10 · ownership.nature: Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, (iv) 353,184 Shares beneficially owned by Fund IV, and (v) 5,827 shares beneficially owned by the Account. Read SEC document
September 29, 2025 Filed Oct 1, 2025 21:22 UTC	MoonLake Immunotherapeutics MLTX · Entity 4785	SaleClass A Ordinary Shares	3,390,943	$7.58	$25,703,347.94	Disclosure SEC source: 0000929638-25-003712 · form4.xml · nonDerivative · entry 3 Chen Bihua · CIK 0001599214 · Former 10% Owner Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 4,800,000 F7 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $7.30 to $8.18 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account. F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F8 · ownership.nature: Represents (i) 1,532,978 Shares beneficially owned by the Master Fund, (ii) 1,018,717 Shares beneficially owned by Fund II, (iii) 1,386,674 Shares beneficially owned by Fund III, (iv) 847,642 Shares beneficially owned by Fund IV, and (v) 13,989 shares beneficially owned by the Account. Read SEC document
September 29, 2025 Filed Oct 1, 2025 21:22 UTC	MoonLake Immunotherapeutics MLTX · Entity 4785	SaleClass A Ordinary Shares	232,460	$8.40	$1,952,664.00	Disclosure SEC source: 0000929638-25-003712 · form4.xml · nonDerivative · entry 2 Chen Bihua · CIK 0001599214 · Former 10% Owner Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 8,190,943 F5 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $8.20 to $9.02 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account. F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6 · ownership.nature: Represents (i) 2,615,943 Shares beneficially owned by the Master Fund, (ii) 1,738,386 Shares beneficially owned by Fund II, (iii) 2,366,285 Shares beneficially owned by Fund III, (iv) 1,446,456 Shares beneficially owned by Fund IV, and (v) 23,873 shares beneficially owned by the Account. Read SEC document
September 29, 2025 Filed Oct 1, 2025 21:22 UTC	MoonLake Immunotherapeutics MLTX · Entity 4785	SaleClass A Ordinary Shares	70,748	$9.38	$663,616.24	Disclosure SEC source: 0000929638-25-003712 · form4.xml · nonDerivative · entry 1 Chen Bihua · CIK 0001599214 · Former 10% Owner Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 8,423,403 F1 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $9.25 to $9.43 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund (as defined below) , Fund II (as defined below), Fund III (as defined below), Fund IV (as defined below), and the Account (as defined below). F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Represents (i) 2,690,183 Shares beneficially owned by the Master Fund, (ii) 1,787,722 Shares beneficially owned by Fund II, (iii) 2,433,441 Shares beneficially owned by Fund III, (iv) 1,487,507 Shares beneficially owned by Fund IV, and (v) 24,550 shares beneficially owned by the Account. Read SEC document
October 05, 2023 Filed Oct 10, 2023 20:00 UTC	MoonLake Immunotherapeutics MLTX · Entity 4785	PurchaseClass A Ordinary Shares	58,839	$59.90	$3,524,297.23	Disclosure SEC source: 0000929638-23-002739 · form4.xml · nonDerivative · entry 1 Chen Bihua · CIK 0001599214 · 10% owner Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 8,494,151 F1 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") purchased in a series of open market transactions on the transaction date at prices ranging from $59.78 to $59.90 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below). F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Represents (i) 2,712,779 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account. Read SEC document
October 04, 2023 Filed Oct 4, 2023 21:52 UTC	MoonLake Immunotherapeutics MLTX · Entity 4785	PurchaseClass A Ordinary Shares	67,814	$57.32	$3,887,017.10	Disclosure SEC source: 0000929638-23-002692 · form4.xml · nonDerivative · entry 3 Chen Bihua · CIK 0001599214 · 10% owner Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 8,435,312 F9 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") purchased in a series of open market transactions on the transaction date at prices ranging from $56.88 to $57.60 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below). F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein reflect a distribution of Shares previously owned by Helix Holdings LLC ("Helix") to the Funds on a pro rata basis in accordance with their interests in Helix. F5 · ownership.nature: Prior to the purchases of Shares reported herein, (i) the Master Fund beneficially owned 2,360,728 Shares, (ii) Fund II beneficially owned 1,802,737 Shares, (iii) Fund III beneficially owned 2,453,879 Shares, (iv) Fund IV beneficially owned 1,500,000 Shares, and (v) the Account beneficially owned 24,756 shares. F10 · ownership.nature: Represents (i) 2,653,940 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account. Read SEC document
October 03, 2023 Filed Oct 4, 2023 21:52 UTC	MoonLake Immunotherapeutics MLTX · Entity 4785	PurchaseClass A Ordinary Shares	150,487	$57.25	$8,615,681.72	Disclosure SEC source: 0000929638-23-002692 · form4.xml · nonDerivative · entry 2 Chen Bihua · CIK 0001599214 · 10% owner Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 8,367,498 F7 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") purchased in a series of open market transactions on the transaction date at prices ranging from $56.87 to $57.50 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below). F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein reflect a distribution of Shares previously owned by Helix Holdings LLC ("Helix") to the Funds on a pro rata basis in accordance with their interests in Helix. F5 · ownership.nature: Prior to the purchases of Shares reported herein, (i) the Master Fund beneficially owned 2,360,728 Shares, (ii) Fund II beneficially owned 1,802,737 Shares, (iii) Fund III beneficially owned 2,453,879 Shares, (iv) Fund IV beneficially owned 1,500,000 Shares, and (v) the Account beneficially owned 24,756 shares. F8 · ownership.nature: Represents (i) 2,586,126 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account. Read SEC document
October 02, 2023 Filed Oct 4, 2023 21:52 UTC	MoonLake Immunotherapeutics MLTX · Entity 4785	PurchaseClass A Ordinary Shares	74,911	$57.37	$4,297,644.07	Disclosure SEC source: 0000929638-23-002692 · form4.xml · nonDerivative · entry 1 Chen Bihua · CIK 0001599214 · 10% owner Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 8,217,011 F1 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") purchased in a series of open market transactions on the transaction date at prices ranging from $56.75 to $57.62 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below). F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein reflect a distribution of Shares previously owned by Helix Holdings LLC ("Helix") to the Funds on a pro rata basis in accordance with their interests in Helix. F5 · ownership.nature: Prior to the purchases of Shares reported herein, (i) the Master Fund beneficially owned 2,360,728 Shares, (ii) Fund II beneficially owned 1,802,737 Shares, (iii) Fund III beneficially owned 2,453,879 Shares, (iv) Fund IV beneficially owned 1,500,000 Shares, and (v) the Account beneficially owned 24,756 shares. F6 · ownership.nature: Represents (i) 2,435,639 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account. Read SEC document
July 20, 2023 Filed Jul 24, 2023 20:01 UTC	GreenLight Biosciences Holdings, PBC GRNA · Entity 111075	SaleCommon Stock	9,188,659	$0.00	$0.00	Disclosure SEC source: 0000929638-23-002058 · form4.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · (See below) Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · (See below) Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · (See below) Chen Bihua · CIK 0001599214 · (See below) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · price: Pursuant to the terms of previously disclosed Contribution and Exchange Agreements, the shares reported herein were contributed to SW ParentCo, Inc. ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.001 per share, of Parent. F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP II, LLC ("GP II") serve as General Partner of the Master Fund and Fund II, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP II. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: Represents (i) 4,751,020 shares of Common Stock that had been beneficially owned by the Master Fund and (ii) 4,437,639 shares of Common Stock that had been beneficially owned by Fund II. Read SEC document
June 22, 2023 Filed Jun 26, 2023 20:06 UTC	Erasca, Inc. ERAS · Entity 3796	GrantStock Option (right to buy) · Derivative	60,000	$0.00 Strike: $2.66	$0.00	Disclosure SEC source: 0000929638-23-001787 · form4.xml · derivative · entry 4 Chen Bihua · CIK 0001599214 · Director Cormorant Asset Management, LP · CIK 0001583977 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Director Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-06-21 F4 · derivative.exercise_date: 100% of the options to purchase shares vest on 6/22/2024, subject to the Reporting Person's continuous service to the Issuer on such vesting date. F5 · ownership.direct: Stock options granted to Bihua Chen, in her capacity as a director of the Issuer. Read SEC document
December 13, 2022 Filed Dec 20, 2022 22:42 UTC	Erasca, Inc. ERAS · Entity 3796	PurchaseCommon Stock	307,692	$6.50	$1,999,998.00	Disclosure SEC source: 0000929638-22-001901 · form4.xml · nonDerivative · entry 1 Chen Bihua · CIK 0001599214 · Director Cormorant Asset Management, LP · CIK 0001583977 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Director Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,813,246 F1 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F2 · ownership.nature: Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account. F3 · ownership.nature: Shares reported herein as purchased on December 9, 2022 were purchased by the Master Fund. Read SEC document
December 13, 2022 Filed Dec 21, 2022 21:33 UTC Amendment	Erasca, Inc. ERAS · Entity 3796	PurchaseCommon Stock	307,692	$6.50	$1,999,998.00	Disclosure SEC source: 0000929638-22-001904 · form4.xml · nonDerivative · entry 1 Chen Bihua · CIK 0001599214 · Director Cormorant Asset Management, LP · CIK 0001583977 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Director Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,813,246 F1 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F2 · ownership.nature: Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account. F3 · ownership.nature: Shares reported herein as purchased on December 9, 2022 were purchased by the Master Fund. Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:10 UTC	Erasca, Inc. ERAS · Entity 3796	ConversionSeries B-2 Convertible Preferred Stock · Derivative	1,388,887	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-013838 · doc1.xml · derivative · entry 5 Chen Bihua · CIK 0001599214 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,388,887 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F7 · ownership.nature: The Series B-2 Convertible Preferred Stock represented, on an as-converted basis, (i) 262,777 shares of Common Stock held by the Master Fund, and (ii) 1,126,110 shares of Common Stock held by Fund II. Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:10 UTC	Erasca, Inc. ERAS · Entity 3796	ConversionSeries B-1 Convertible Preferred Stock · Derivative	4,166,666	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-013838 · doc1.xml · derivative · entry 4 Chen Bihua · CIK 0001599214 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 4,166,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6 · ownership.nature: The Series B-1 Convertible Preferred Stock represented, on an as-converted basis, (i)788,333 shares of Common Stock held by the Master Fund, and (ii) 3,378,333 shares of Common Stock held by Fund II. Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:10 UTC	Erasca, Inc. ERAS · Entity 3796	ConversionSeries A Convertible Preferred Stock · Derivative	4,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-013838 · doc1.xml · derivative · entry 3 Chen Bihua · CIK 0001599214 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 4,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5 · ownership.nature: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 677,600 shares of Common Stock held by the Master Fund, (ii) 3,212,000 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account. Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:10 UTC	Erasca, Inc. ERAS · Entity 3796	PurchaseCommon Stock	950,000	$16.00	$15,200,000.00	Disclosure SEC source: 0001567619-21-013838 · doc1.xml · nonDerivative · entry 2 Chen Bihua · CIK 0001599214 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,505,553 F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein as purchased on July 20, 2021 represent 950,000 shares purchased by the Master Fund. Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:10 UTC	Erasca, Inc. ERAS · Entity 3796	ConversionCommon Stock	9,555,553	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-013838 · doc1.xml · nonDerivative · entry 1 Chen Bihua · CIK 0001599214 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 9,555,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: Represents (i) 1,728,710 shares of Common Stock held by the Master Fund, (ii) 7,716,443 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account. Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:45 UTC	Jade Biosciences, Inc. AVTE · Entity 4757	ConversionSeries A Convertible Preferred Stock · Derivative	1,530,691	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-013070 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,530,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund II. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5 · ownership.nature: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 318,995 shares of Common Stock held by the Master Fund and (ii) 1,211,696 shares of Common Stock held by Fund II. Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:45 UTC	Jade Biosciences, Inc. AVTE · Entity 4757	PurchaseCommon Stock	500,000	$14.00	$7,000,000.00	Disclosure SEC source: 0001567619-21-013070 · doc1.xml · nonDerivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,030,691 F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund II. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein as purchased on July 2, 2021 represent 500,000 shares purchased by the Master Fund. Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:45 UTC	Jade Biosciences, Inc. AVTE · Entity 4757	ConversionCommon Stock	1,530,691	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-013070 · doc1.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,530,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund II. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: Represents (i) 318,995 shares of Common Stock held by the Master Fund and (ii) 1,211,696 shares of Common Stock held by Fund II. Read SEC document
June 28, 2021 Filed Jun 30, 2021 20:08 UTC	Monte Rosa Therapeutics, Inc. GLUE · Entity 4828	ConversionSeries C Convertible Preferred Stock · Derivative	477,857	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-012781 · doc1.xml · derivative · entry 4 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 477,857 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6 · ownership.nature: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 104,650 shares of Common Stock held by the Master Fund, (ii) 364,725 shares of Common Stock held by Fund III, and (iii) 8,482 shares of Common Stock held by the Account. Read SEC document
June 28, 2021 Filed Jun 30, 2021 20:08 UTC	Monte Rosa Therapeutics, Inc. GLUE · Entity 4828	ConversionSeries B Convertible Preferred Stock · Derivative	2,124,343	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-012781 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,124,343 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5 · ownership.nature: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 226,242 shares of Common Stock held by the Master Fund, (ii) 843,577 shares of Common Stock held by Fund II, and (iii) 1,054,524 shares of Common Stock held by Fund III. Read SEC document
June 28, 2021 Filed Jun 30, 2021 20:08 UTC	Monte Rosa Therapeutics, Inc. GLUE · Entity 4828	PurchaseCommon Stock	600,000	$19.00	$11,400,000.00	Disclosure SEC source: 0001567619-21-012781 · doc1.xml · nonDerivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,202,200 F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein as purchased on June 28, 2021 represent 600,000 shares purchased by the Master Fund. Read SEC document
June 28, 2021 Filed Jun 30, 2021 20:08 UTC	Monte Rosa Therapeutics, Inc. GLUE · Entity 4828	ConversionCommon Stock	2,602,200	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-012781 · doc1.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,602,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: Represents (i) 330,892 shares of Common Stock held by the Master Fund, (ii) 843,577 shares of Common Stock held by Fund II, (iii) 1,419,249 shares of Common Stock held by Fund III, and (iv) 8,482 shares of Common Stock held by the Account. Read SEC document
April 27, 2021 Filed Apr 29, 2021 20:02 UTC	Rain Oncology Inc. RAIN · Entity 94695	ConversionSeries B Convertible Preferred Stock · Derivative	2,512,561	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-008744 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,326,657 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5 · ownership.nature: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 133,980 shares of voting common stock and 109,620 shares of non-voting common stock held by the Master Fund, (ii) 509,177 shares of voting common stock and 416,600 shares of non-voting common stock held by Fund II, and (iii) 636,504 shares of voting common stock and 520,776 shares of non-voting common stock held by the Fund III Read SEC document
April 27, 2021 Filed Apr 29, 2021 20:02 UTC	Rain Oncology Inc. RAIN · Entity 94695	PurchaseCommon Stock	450,000	$17.00	$7,650,000.00	Disclosure SEC source: 0001567619-21-008744 · doc1.xml · nonDerivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,776,657 F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein as purchased on April 27, 2021 represent (i) 439,425 shares purchased by the Master Fund, and (ii) 10,575 shares purchased by the Account. Read SEC document
April 27, 2021 Filed Apr 29, 2021 20:02 UTC	Rain Oncology Inc. RAIN · Entity 94695	ConversionCommon Stock	2,326,657	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-008744 · doc1.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,326,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: Represents (i) 133,980 shares of voting common stock and 109,620 shares of non-voting common stock held by the Master Fund, (ii) 509,177 shares of voting common stock and 416,600 shares of non-voting common stock held by Fund II, and (iii) 636,504 shares of voting common stock and 520,776 shares of non-voting common stock held by the Fund III. Read SEC document
March 30, 2021 Filed Apr 1, 2021 20:15 UTC	Design Therapeutics, Inc. DSGN · Entity 4991	ConversionSeries B Convertible Preferred Stock · Derivative	1,404,953	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-007374 · doc1.xml · derivative · entry 4 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,404,953 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6 · ownership.nature: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 298,552 shares held by the Master Fund, (ii) 1,084,906 shares held by Fund III, and (iii) 21,495 shares held by the Account. Read SEC document
March 30, 2021 Filed Apr 1, 2021 20:15 UTC	Design Therapeutics, Inc. DSGN · Entity 4991	ConversionSeries A Convertible Preferred Stock · Derivative	2,959,891	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-007374 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,959,891 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5 · ownership.nature: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 588,988 shares held by the Master Fund, (ii) 2,335,405 shares held by Fund II, and (iii) 35,498 shares held by the Account. Read SEC document
March 30, 2021 Filed Apr 1, 2021 20:15 UTC	Design Therapeutics, Inc. DSGN · Entity 4991	PurchaseCommon Stock	750,000	$20.00	$15,000,000.00	Disclosure SEC source: 0001567619-21-007374 · doc1.xml · nonDerivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,114,844 F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein as purchased on March 30, 2021 represent (i) 713,850 shares purchased by the Master Fund, and (ii) 36,150 shares purchased by the Account. Read SEC document
March 30, 2021 Filed Apr 1, 2021 20:15 UTC	Design Therapeutics, Inc. DSGN · Entity 4991	ConversionCommon Stock	4,364,844	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-007374 · doc1.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,364,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: Represents (i) 887,540 shares of Common Stock held by the Master Fund, (ii) 2,335,405 shares held by Fund II, (iii) 1,084,906 shares of Common Stock held by Fund III, and (iv) 56,993 shares of Common Stock held by the Account. Read SEC document
December 18, 2020 Filed Dec 22, 2020 21:09 UTC	BioAtla, Inc. BCAB · Entity 879	ConversionSeries D Convertible Preferred Stock · Derivative	1,492,060	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-021488 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,492,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series D Convertible Preferred Stock ("Series D Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series D Convertible Preferred Stock ("Series D Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series D Convertible Preferred Stock ("Series D Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series D Convertible Preferred Stock ("Series D Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II") and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: The Series D Preferred Stock represented, on an as-converted basis (i) 310,945 shares of Common Stock held by the Master Fund and (ii) 1,181,115 shares of Common Stock held by Fund II. Read SEC document
December 18, 2020 Filed Dec 22, 2020 21:09 UTC	BioAtla, Inc. BCAB · Entity 879	PurchaseCommon Stock	800,000	$18.00	$14,400,000.00	Disclosure SEC source: 0001567619-20-021488 · doc1.xml · nonDerivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,292,060 F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II") and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein as purchased on December 18, 2020 represent (i) 765,120 shares purchased by the Master Fund, and (ii) 34,880 shares purchased by the Account. Read SEC document
December 18, 2020 Filed Dec 22, 2020 21:09 UTC	BioAtla, Inc. BCAB · Entity 879	ConversionCommon Stock	1,492,060	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-021488 · doc1.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,492,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series D Convertible Preferred Stock ("Series D Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II") and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: The Series D Preferred Stock represented, on an as-converted basis (i) 310,945 shares of Common Stock held by the Master Fund and (ii) 1,181,115 shares of Common Stock held by Fund II. Read SEC document
November 23, 2020 Filed Nov 23, 2020 21:59 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	ConversionSeries C Convertible Preferred Stock · Derivative	723,177	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-020222 · doc1.xml · derivative · entry 4 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 723,177 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6 · ownership.nature: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 126,122 shares held by the Master Fund, (ii) 587,871 shares held by Fund III, and (iii) 9,184 shares held by the Account. Read SEC document
November 23, 2020 Filed Nov 23, 2020 21:59 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	ConversionSeries B Convertible Preferred Stock · Derivative	2,122,367	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-020222 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,122,367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5 · ownership.nature: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 412,342 shares held by the Master Fund, (ii) 1,684,920 shares held by Fund II, and (iii) 25,105 shares held by the Account. Read SEC document
November 23, 2020 Filed Nov 23, 2020 21:59 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	PurchaseCommon Stock	425,000	$19.00	$8,075,000.00	Disclosure SEC source: 0001567619-20-020222 · doc1.xml · nonDerivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,270,544 F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein as purchased on November 23, 2020 represent (i) 404,940 shares purchased by the Master Fund, and (ii) 20,060 shares purchased by the Account. Read SEC document
November 23, 2020 Filed Nov 23, 2020 21:59 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	ConversionCommon Stock	2,845,544	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-020222 · doc1.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,845,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: Represents (i) 538,464 shares of Common Stock held by the Master Fund, (ii) 1,684,920 shares of Common Stock held by Fund II, (iii) 587,871 shares of Common Stock held by Fund III, and (iv) 34,289 shares of Common Stock held by the Account. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionSeries D-1 Convertible Preferred Stock · Derivative	417,360	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · derivative · entry 6 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 417,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F8 · ownership.nature: The Series D-1 Convertible Preferred Stock represented, on an as-converted basis, (i) 80,175 shares held by the Master Fund and (ii) 337,185 shares held by Fund II. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionSeries D Convertible Preferred Stock · Derivative	712,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · derivative · entry 5 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 712,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F7 · ownership.nature: The Series D Convertible Preferred Stock represented, on an as-converted basis, (i) 136,823 shares held by the Master Fund and (ii) 575,427 shares held by Fund II. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionSeries C Convertible Preferred Stock · Derivative	2,631,580	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · derivative · entry 4 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,631,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6 · ownership.nature: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 587,632 shares held by the Master Fund, (ii) 1,951,053 shares held by Fund I, and (iii) 92,895 shares held by the Account. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionSeries B Convertible Preferred Stock · Derivative	1,650,165	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,650,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5 · ownership.nature: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 396,040 shares held by the Master Fund, (ii) 1,155,115 shares held by Fund I, and (iii) 99,010 shares held by the Account. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionSeries A Convertible Preferred Stock · Derivative	1,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · derivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 842,500 shares held by the Master Fund and (ii) 157,500 shares held by the Account. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionCommon Stock	6,411,355	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,411,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: Represents (i) 2,043,170 shares of Common Stock held by the Master Fund, (ii) 3,106,168 shares of Common Stock held by Fund I, (iii) 912,612 shares of Common Stock held by Fund II, and (iv) 349,405 shares of Common Stock held by the Account. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:00 UTC	Akouos, Inc. AKUS · Entity 11574	ConversionSeries B Convertible Preferred Stock · Derivative	499,989	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-012814 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 499,989 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B Convertible Preferred Stock ("Series B Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series B Convertible Preferred Stock ("Series B Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series B Convertible Preferred Stock ("Series B Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series B Convertible Preferred Stock ("Series B Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F3 · ownership.nature: The Series B Preferred Stock represented, on an as-converted basis (i) 99,493 shares of Common Stock held by the Master Fund, (ii) 394,500 shares of Common Stock held by Fund II, and (iii) 5,996 shares of Common Stock held by the Account. F4 · ownership.nature: Shares reported herein as purchased on June 30, 2020 represent (i) 274,543 shares purchased by the Master Fund, and (ii) 15,457 shares purchased by the Account. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:00 UTC	Akouos, Inc. AKUS · Entity 11574	PurchaseCommon Stock	290,000	$17.00	$4,930,000.00	Disclosure SEC source: 0001567619-20-012814 · doc1.xml · nonDerivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 789,989 F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein as purchased on June 30, 2020 represent (i) 274,543 shares purchased by the Master Fund, and (ii) 15,457 shares purchased by the Account. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:00 UTC	Akouos, Inc. AKUS · Entity 11574	ConversionCommon Stock	499,989	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-012814 · doc1.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 499,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B Convertible Preferred Stock ("Series B Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: The Series B Preferred Stock represented, on an as-converted basis (i) 99,493 shares of Common Stock held by the Master Fund, (ii) 394,500 shares of Common Stock held by Fund II, and (iii) 5,996 shares of Common Stock held by the Account. Read SEC document
June 16, 2020 Filed Jun 18, 2020 20:02 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	ConversionSeries C Convertible Preferred Stock · Derivative	2,214,545	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-012364 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,214,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series C Convertible Preferred Stock ("Series C Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series C Convertible Preferred Stock ("Series C Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series C Convertible Preferred Stock ("Series C Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series C Convertible Preferred Stock ("Series C Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering. F3 · ownership.direct: The Series C Preferred Stock represented, on an as-converted basis (i) 419,877 shares of Common Stock held by the Master Fund, (ii) 1,762,115 shares of Common Stock held by Fund II, and (iii) 32,553 shares of Common Stock held by the Account. F4 · ownership.direct: Shares reported herein as purchased on June 16, 2020 represent (i) 284,010 shares purchased by the Master Fund, and (ii) 15,990 shares purchased by the Account. Read SEC document
June 16, 2020 Filed Jun 18, 2020 20:02 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	PurchaseCommon Stock	300,000	$18.00	$5,400,000.00	Disclosure SEC source: 0001567619-20-012364 · doc1.xml · nonDerivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,514,545 F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein as purchased on June 16, 2020 represent (i) 284,010 shares purchased by the Master Fund, and (ii) 15,990 shares purchased by the Account. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.